8.27

2.25% -0.19

After Hours: 8.25 -0.02 -0.24%

Bridgebio Oncology Therapeutics Inc (BBOT)

Overview News Price History Discussions Forecast

Bridgebio Oncology Therapeutics Inc stock is traded at $8.27, with a volume of 173.57K. It is down -2.25% in the last 24 hours and down -7.18% over the past month. BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Previous Close:

$8.46

Open:

$8.51

24h Volume:

173.57K

Relative Volume:

0.56

Market Cap:

$662.53M

Revenue:

Net Income/Loss:

$-83.12M

P/E Ratio:

-5.5292

EPS:

-1.4957

Net Cash Flow:

$-114.50M

1W Performance:

-6.02%

1M Performance:

-7.18%

6M Performance:

-33.31%

1Y Performance:

+0.00%

1-Day Range:

$8.1489

$8.665

1-Week Range:

$8.00

$9.00

52-Week Range:

$8.00

$14.87

Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile

Name

Bridgebio Oncology Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

857 702 0377

Address

256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-06-04

Latest SEC Filings

BBOT's Discussions on Twitter

Compare BBOT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BBOT Bridgebio Oncology Therapeutics Inc	8.27	677.75M	0	-83.12M	-114.50M	-1.4957
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-26	Initiated	Stifel	Buy
Jan-09-26	Initiated	Raymond James	Outperform
Dec-05-25	Initiated	Morgan Stanley	Overweight
Sep-17-25	Initiated	Leerink Partners	Outperform
Sep-15-25	Initiated	H.C. Wainwright	Buy
Aug-15-25	Initiated	Piper Sandler	Overweight

View All

Bridgebio Oncology Therapeutics Inc Stock (BBOT) Latest News

May 05, 2026

[EFFECT] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan

May 05, 2026

May 04, 2026

BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price Today & Analysis - Gotrade

May 04, 2026

Apr 30, 2026

BBOT (NASDAQ: BBOT) registers 63.05M common shares for resale - Stock Titan

Apr 30, 2026

BridgeBio Oncology (NASDAQ: BBOT) accounting chief reports initial equity stake - Stock Titan

Apr 30, 2026

BridgeBio Oncology (NASDAQ: BBOT) COO Idan details initial stock and option holdings - Stock Titan

Apr 30, 2026

BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 30, 2026

The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media

Apr 30, 2026

Apr 29, 2026

63.05M shares registered; CEO change and consulting deal at BridgeBio Oncology (BBOT) - Stock Titan

Apr 29, 2026

Ex-CEO Wallace stays advisor at BridgeBio Oncology (BBOT) - Stock Titan

Apr 29, 2026

Apr 28, 2026

[ARS] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan

Apr 28, 2026

BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan

Apr 28, 2026

H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy By Investing.com - Investing.com India

Apr 24, 2026

H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy - Investing.com

Apr 24, 2026

Apr 23, 2026

Stifel Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $23 - Moomoo

Apr 23, 2026

BridgeBio (BBOT) Stock: Price Pattern Formation | Q4 2025: EPS Beats ForecastsDividend Growth Rate - Xã Thanh Hà

Apr 23, 2026

BridgeBio Oncology Overhauls Leadership for Next Development Phase - TipRanks

Apr 23, 2026

BridgeBio Oncology names Pedro Beltran as new CEO By Investing.com - Investing.com India

Apr 23, 2026

Apr 22, 2026

BridgeBio Oncology Therapeutics (BBOT) registers 63.1M shares; Beltran named CEO - Stock Titan

Apr 22, 2026

New leadership team takes shape at BridgeBio Oncology (Nasdaq: BBOT) - Stock Titan

Apr 22, 2026

BBOT Presents Preclinical Data Demonstrating pan-KRAS - GlobeNewswire

Apr 22, 2026

BridgeBio Oncology names Pedro Beltran as new CEO - Investing.com

Apr 22, 2026

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - marketscreener.com

Apr 22, 2026

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as - GlobeNewswire

Apr 22, 2026

Apr 21, 2026

BridgeBio Oncology presents preclinical data on BBO-10203 By Investing.com - Investing.com South Africa

Apr 21, 2026

BridgeBio Oncology presents preclinical data on BBO-10203 - Investing.com

Apr 21, 2026

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker - GlobeNewswire

Apr 21, 2026

BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution (NASDAQ:BBOT) - Seeking Alpha

Apr 21, 2026

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - Yahoo Finance

Apr 21, 2026

Apr 20, 2026

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT - Moomoo

Apr 20, 2026

BridgeBio Reports FDA Fast Track Label for BBO-11818 - Moomoo

Apr 20, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 20, 2026

BridgeBio Oncology Therapeutics stock jumps 10% on FDA nod By Investing.com - Investing.com Nigeria

Apr 20, 2026

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment - marketscreener.com

Apr 20, 2026

FDA grants fast track status to BridgeBio’s pancreatic cancer drug By Investing.com - Investing.com Canada

Apr 20, 2026

BridgeBio Oncology Therapeutics, Inc recently revealed that the eagerly awaited updated data from its Phase I clinical trial is expected to be released in the second half of 2026. - Bitget

Apr 20, 2026